Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide vs Oxygen for Pulmonary Vasoreactivity Testing
NCT00626028Phase 3Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Sep 2004
- Primary completion
- Feb 2010
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of nitric oxide in pulmonary hypertension (PH) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoint: Number of Participants With Reversible Pulmonary Hypertension (Vasoreactivity) at Day 1. Started Sep 2004; status: completed.
02
Drugs
nitric oxide
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT00626028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626028.